VEGFA and glaucoma: For the PDR eyes, having this level of final vision was associated with having worse VA at presentation (p = 0.023), not being on or not starting a prostaglandin analogue (PGA) at presentation (p < 0.001), not receiving an intravitreal anti-VEGF injection at or before presentation (p = 0.046), and fewer glaucoma drops initiated (or already being used) at presentation (p = 0.009).